Neulasta in Type 1 Diabetes
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Neulasta in Type 1 Diabetes is a clinical trial[1].
Key Facts
- Neulasta in Type 1 Diabetes is in the country of United States[2].
- Neulasta in Type 1 Diabetes's instance of is recorded as clinical trial[3].
- Neulasta in Type 1 Diabetes's start time is recorded as +2008-04-30T00:00:00Z[4].
- Neulasta in Type 1 Diabetes's end time is recorded as +2014-03-31T00:00:00Z[5].
- Neulasta in Type 1 Diabetes's sponsor is recorded as University of Florida[6].
- Neulasta in Type 1 Diabetes's main subject is recorded as diabetes[7].
- Neulasta in Type 1 Diabetes's number of participants is recorded as {'unit': '1', 'amount': '+21'}[8].
- Neulasta in Type 1 Diabetes's title is recorded as Short Course of Pegylated GCSF (Neulasta®) as Immunomodulatory Therapy for Type 1 Diabetes[9].
- Neulasta in Type 1 Diabetes's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+12'}[10].
- Neulasta in Type 1 Diabetes's ClinicalTrials.gov ID is recorded as NCT00662519[11].
- Neulasta in Type 1 Diabetes's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}[12].
- Neulasta in Type 1 Diabetes's research intervention is recorded as sargramostim[13].
- Neulasta in Type 1 Diabetes's clinical trial phase is recorded as phase I clinical trial[14].
- Neulasta in Type 1 Diabetes's research site is recorded as University of Florida[15].
- Neulasta in Type 1 Diabetes's study type is recorded as interventional study[16].